Paclitaxel, carboplatin and gemcitabine combination as induction chemotherapy for stage IIIA N2 bulky non-small cell lung cancer

Oncology

Volumn 69, Issue 4, 2005, Pages 295-300

  Giannitto, Giorgio Carmelo ^a   Giuffrida, Dario ^b   Pappalardo, Alessandro ^c   Russo, Antonio ^d   Vincenzi, Bruno ^e,h   Saita, Salvino ^f   Potenza, Enrico ^f   Marletta, Franco ^f   La Venia, Giuseppe ^g   Castorina, Sergio ^g   Bordonaro, Roberto ^g  

^a Gravina Hospital   (Italy)

^b Oncology Unit Mediterranean Institute of Oncology   (Italy)

^c Casa Sollievo Sofferenza   (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

^e Medical Oncology   (Italy)

^f S Luigi Hospital   (Italy)

^g UNIVERSITY OF CATANIA   (Italy)

^h UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Carboplatin, stage III; Chemotherapy; Lung cancer; Paclitaxel

Indexed keywords

ALANINE AMINOTRANSFERASE; CARBOPLATIN; GEMCITABINE; PACLITAXEL;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CHEMOTHERAPY INDUCED EMESIS; CYTOLOGY; DIARRHEA; DISEASE SEVERITY; DRUG FATALITY; DRUG RESPONSE; FEBRILE NEUTROPENIA; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM LYMPH NODE; MORBIDITY; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTOPENIA; TUMOR BIOPSY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; RADIOTHERAPY, ADJUVANT; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 28644445227     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089679     Document Type: Article

References (29)

1. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics, 1997. CA Cancer J Clin 1997;47: 5-27.
2. Martini N, Kris MG, Flehinger BJ, Gralla RJ, Bains MS, Burt ME, Heelan R, McCormack PM, Pisters KM, Rigas JR: Preoperative chemotherapy for stage IIIA (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg 1993;55:1365-1374.
3. Burkes RL, Ginsberg RJ, Shepherd FA, Blackstein ME, Goldberg ME, Waters PF, Patterson GA, Todd T, Pearson FG, Cooper JD: Induction chemotherapy with mitomycin, vindesine and cisplatin for stage III unresectable non-small cell lung cancer: results of the Toronto phase II trial. J Clin Oncol 1992;10:580-586.
4. Elias AD, Skarin AT, Leong T, Mentzer S, Strauss G, Lynch T, Shulman L, Jacobs C, Abner A, Baldini EH, Frei E 3rd, Sugarbaker DJ: Neoadjuvant therapy for surgically staged IIA N2 non-small cell lung cancer. Lung Cancer 1997;17:147-161.
5. Pass HI, Pogrebniak HW, Steinberg SM, Mulshine J. Minna J: Randomized trial of neo-adjuvant therapy for lung cancer: interim anal-ysis. Ann Thorac Surg 1992;53:992-998.
6. Roth JA, Fossella F, Komaki R, Ryan MB, Putnam JB Jr, Lee JS, Dhingra H, De Caro L, Chasen M, McGavran M: A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIA non-small cell lung cancer. J Natl Cancer Inst 1994;86:673-680.
7. Rosell R, Gomez-Codina J, Camps C, Maestre J, Padille J, Canto A, Mate JL, Li S, Roig J, Olazabal A: A randomised trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. N Engl J Med 1994;330:153-158.
8. Rosell R, Gomez-Codina J, Camps C, Javier Sanchez J, Maestre J, Padilla J, Canto A, Abad A, Roig J: Preresectional chemotherapy in stage IIIA non-small cell lung cancer: a 7-year assessment of a randomised trial. Lung Cancer 1999;47:7-14.
9. Roth JA, Atkinson EN, Fossella F, Komaki R, Bernadette Ryan M, Putnam JB Jr, Lee JS, Dhingra H, De Caro L, Chasen M, Hong WK: Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIA non-small-cell lung cancer. Lung Cancer 1998;21:1-6.
10. Simon R: Optimal two-stage design for phase II clinical trials. Control Clin Trials 1989;10:1-10.
11. Cancer Therapy Evaluation Program, Common Toxicity Criteria, Version 2.0. https://webapss.ctep.nci.nih.gov/ctcv2/1999.
12. Kaplan EI, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
13. Elias A, Herdan J, Kurnar P, et al: A phase III comparison of 'best local-regional therapy' with or without chemotherapy for stage IIIA T1-3N2 non-small cell lung cancer (NSCLC). Preliminary results (abstract A1 622). Proc Am Soc Clin Oncol 1997.
14. Fleck J, Camargo K, Godoy D, et al: Chemoradiation therapy versus chemotherapy alone as a neo-adjuvant treatment for stage III non-small cell lung cancer. Preliminary report of a phase III prospective randomised trial (abstract A1 105). Proc Am Soc Clin Oncol 1997.
15. Nagai K, Tsuchiya R, Mori T, Tada H, Ichinose Y, Koike T, Kato H; Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group: A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG9209). J Thorac Cardiovasc Surg 2003;125:254-260.
16. Depierre A, Milleron B, Moro-Sibilot D, Chevret S, Quoix E, Lebeau B, Braun D, Breton JL, Lemarie E, Gouva S, Paillot N, Brechot JM, Janicot H, Lebas FX, Terrioux P, Clavier J, Foucher P, Monchatre M, Coetmeur D, Level MC, Leclerc P, Blanchon F, Rodier JM, Thiberville L, Villeneuve A, Westeel V, Chastang C; French Thoracic Cooperative Group: Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIA non-small cell lung cancer. J Clin Oncol 2002;20:247-253.
17. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995;311:899-909.
18. Pritchard RS, Anthony SP: Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small cell lung cancer. A meta-analysis. Ann Intern Med 1996;125:723-729.
19. Mariano P, Preatoni A, Cantoni A: Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIA and IIIB non-small cell lung cancer. Cancer 1995;76:593-601.
20. Dillman RO, Herndon J, Seagren SL, Eaton WL Jr, Green MR: Improved survival in stage III non-small-cell lung cancer: seven-year follow-up cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996;88:1210-1215.
21. Sause WT, Scott C, Taylor S, Johnson D, Livingston R, Komaki R, Emami B, Curran WJ, Byhardt RW, Turrisi AT, et al: Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995;87:198-205.
22. Le Chevalier T, Arriagada R, Quoix E, Ruffie P, Martin M, Tarayre M, Lacombe-Terrier MJ, Douillard JY, Laplanche A: Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991;83:417-423.
23. O'Brien ME, Splinter T, Smit EF, Biesma B, Krzakowski M, Tjan-Heijnen VC, Van Bochove A, Stigt J, Smid-Geirnaerdt MJ, Debruyne C, Legrand C, Giaccone G; EORTC Lung Cancer Group: Carboplatin and paclitaxol (Taxol) as an induction regimen patients with biopsy-proven stage IIIA N2 non-small cell lung cancer: an EORTC phase II study (EORTC 08958). Eur J Cancer 2003;39:1416-1422.
24. Langer C: Concurrent chemoradiation using paclitaxel and carboplatin in locally advanced non-small cell lung cancer. Semin Radiat Oncol 1999;9:105-116.
25. Hainsworth JD, Burris HA 3rd, Erland JB, Morrissey LH, Meluch AA, Kalman LA, Hon JK, Scullin DC Jr, Smith SW, Greco FA: Phase I/II trial of paclitaxel, by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced non-small cell lung carcinoma. Cancer 1999;85:1269-1276.
26. Kelly K, Mikhaeel-Kamel N, Pan Z, Murphy J, Prindiville S, Bunn PA Jr: A phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer. Clin Cancer Res 2000;6:3474-3479.
27. Favaretto A, Ceresoli GL, Paccagnella A, Barbieri F, Bearz A, Ghiotto C, Oniga F, Schiavon S, Frustaci S, Villa E: Paclitaxel and carboplatin in combination with gemcitabine: a phase I-II trial in patients with advanced non-small-cell lung cancer. Gruppo Studio Tumori Polmonari Veneto (GSTPV). Ann Oncol 2000;11:1421-1426.
28. Hussein A, Birch R, Walzer J, et al: Preliminary results of a randomized study comparing paclitaxel and carboplatin (PC) with or without gemcitabine (G) in newly diagnosed non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2000 (abstr 1973).
29. Paccagnella A, Favaretto A, Oniga F, et al: Paclitaxel/carboplatin (PC) versus paclitaxel/carboplatin/gemcitabine (PCG) in advanced NSCLC: preliminary results of a phase II-III study (abstract 488PD). Ann Oncol 2002.